Registered Number 03357249
MAELOR LABORATORIES LIMITED
Abbreviated Accounts
30 June 2015
Notes | 2015 | 2014 | |
---|---|---|---|
£ | £ | ||
Called up share capital not paid |
|
|
|
Fixed assets | |||
Intangible assets |
|
|
|
Tangible assets |
|
|
|
Investments |
|
|
|
|
|
||
Current assets | |||
Stocks |
|
|
|
Debtors |
|
|
|
Investments |
|
|
|
Cash at bank and in hand |
|
|
|
|
|
||
Prepayments and accrued income |
|
|
|
Creditors: amounts falling due within one year |
|
|
|
Net current assets (liabilities) |
|
|
|
Total assets less current liabilities |
|
|
|
Creditors: amounts falling due after more than one year |
|
|
|
Provisions for liabilities |
|
|
|
Accruals and deferred income |
|
|
|
Total net assets (liabilities) |
|
|
|
Capital and reserves | |||
Called up share capital |
|
|
|
Share premium account |
|
|
|
Revaluation reserve |
|
|
|
Other reserves |
|
|
|
Profit and loss account |
|
|
|
Shareholders' funds |
|
|
Approved by the Board on
And signed on their behalf by:
1 Accounting Policies
Basis of measurement and preparation of accounts
2. The company did not trade during the year, therefore there are no transactions on the profit and loss account.
3. The company is a subsidiary undertaking of IS Pharma Ltd which is the immediate holding company. IS Pharma Ltd is a subsidiary of Sinclair Pharma Holdings ltd, which is a subsidiary of Sinclair IS Pharma plc. All companies are incorporated in England. Sinclair IS Pharma plc is the ultimate parent company by virtue of its controlling interest in the share capital of Sinclair Pharma Holdings Ltd. Sinclair IS Pharma plc is preparing group accounts including the group financial statements of IS Pharma ltd and Sinclair Pharma Holdings Ltd.
4. Post balance sheet events
On 10 December 2015, the Company entered into a framework agreement with Sinclair IS Pharma plc, under which various businesses and assets of certain pharmaceutical and medical device products were transferred to the Company as part of a Group restructuring. Under the framework agreement, the total consideration for the transfer of the business and assets was £59,700,000 which was satisfied by the issue of interest bearing promissory notes to each transferring company. Following the transfer of these businesses and assets the Company began trading on 10 December 2015.
On 17 December 2015, the Company was sold to Alliance Pharmaceuticals Limited, which became the immediate parent undertaking, as part of the disposal of the Sinclair IS Pharma plc’s non-aesthetics business. This resulted in the sale by each former group undertaking of their promissory notes to Alliance Pharmaceuticals Limited for cash consideration of £59,700,000. Alliance Pharmaceuticals Limited is a subsidiary of Alliance Pharma plc, which became the ultimate parent undertaking.